Advertisement

No significant benefit with Umifenovir in treating mild Covid: Glenmark

Follow The Hawk on Google News+ Follow

Advertisement


New Delhi: Glenmark Pharma announced on Friday that the addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in

moderate Covid-19 patients.

Advertisement

It said no significant clinical benefit was seen with the addition of Umifenovir in Covid-19 treatment, as per the Glenmark clinical study. The addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate Covid-19 patients, it added.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment and the trial did not meet the key end-points.

Glenmark on Friday announced the results of its "FAITH" combination trial with antivirals Umifenovir and Favipiravir for the treatment of moderate hospitalised Covid-19 patients.

Advertisement

This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the emergency use authorisation for Favipiravir.

Also read'Fatty liver-free campaign' in Ranchi from Nov 23, MoS Sanjay Seth to take lead

This second study titled the FAITH trial evaluated the possible superiority of the

combination's efficacy against Favipiravir monotherapy.

As per the results that Glenmark presented to the regulator on Friday, the study showed no superior clinical outcomes with the addition of Umifenovir. The FAITH study enrolled 158 hospitalised patients with moderate Covid-19 in India.

The study's primary end point (clinical outcome measured) was the time taken from randomisation to clinical cure, defined as resolution of baseline clinical signs and symptoms of Covid-19 infection and at least 2-point improvement on WHO Ordinal Scale for Clinical Improvement, within a time frame of 28 days.

Median time to clinical cure improved by only 1 day (7 as compared to 8) in patients who

received the two antiviral combination, which was not statistically significant and did not justify adding two antiviral agents.

Commenting on the trial's findings, Monika Tandon, Senior Vice President and Head, Clinical Development, Global Specialty/Branded Portfolio, Glenmark Pharmaceuticals Ltd., said, "Glenmark was the first company to provide patients an oral antiviral treatment for Covid-19 in India, and this combination study was yet another effort on our part to examine new treatment options to combat the health crisis.

"These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate Covid-19 infection."

—IANS

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST